| Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm |
| Cash burn (monthly) | 16.57 mm | 6.14 mm | 13.41 mm | 11.76 mm | 13.25 mm | 10.43 mm |
| Cash used (since last report) | 742.06 mm | 274.94 mm | 600.48 mm | 526.63 mm | 593.20 mm | 466.98 mm |
| Cash remaining | -624.84 mm | -157.73 mm | -483.27 mm | -409.41 mm | -475.98 mm | -349.77 mm |
| Runway (months of cash) | -37.7 | -25.7 | -36.0 | -34.8 | -35.9 | -33.5 |
| 13F holders | Current |
|---|---|
| Total holders | 3 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 131.03 mm |
| Total shares | 5.60 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Column Group L P | 2.58 mm | $74.45 mm |
| Venrock Associates V | 1.74 mm | $20.00 mm |
| Bain Capital Life Sciences Fund | 1.27 mm | $36.58 mm |
